Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership SummitGlobeNewsWire • 03/16/23
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT' Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)GlobeNewsWire • 03/16/23
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsGlobeNewsWire • 03/13/23
Tonix Pharmaceuticals Announces Results from a Preclinical Study of Murine TNX-1700 Presented in a Poster at the Keystone Symposia, “Cancer Immunotherapy: Mechanisms of Response Versus Resistance”GlobeNewsWire • 03/07/23
Tonix Pharmaceuticals obtains exclusive license to develop fully human and murine anti-SARS-CoV-2 monoclonal antibodiesProactive Investors • 02/13/23
Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal AntibodiesGlobeNewsWire • 02/13/23
Tonix Pharmaceuticals Announces Publication of Paper in Viruses Highlighting the Company's Development of a Vaccine to Protect Against Monkeypox and Smallpox (TNX-801)GlobeNewsWire • 02/09/23
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘PREVENTION' Study of Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headaches in Chronic MigraineursGlobeNewsWire • 02/06/23
Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.GlobeNewsWire • 02/02/23
Tonix Pharmaceuticals Announces Research Agreement with University of Maryland, Baltimore, to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Heart Xenograft Transplantation in AnimalsGlobeNewsWire • 02/01/23
Tonix Pharmaceuticals Announces Presentation of Clinical and Non-Clinical TNX-1900 Data at the Annual Headache Cooperative of the Pacific (HCOP) Winter ConferenceGlobeNewsWire • 01/31/23
Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 2nd Wnt & β-catenin Targeted Drug Development ConferenceGlobeNewsWire • 01/26/23
Tonix Pharmaceuticals Announces Publication of Paper in Antiviral Research Highlighting the Company's Development of Monoclonal Antibody Therapeutics for Monkeypox and SmallpoxGlobeNewsWire • 01/24/23
Tonix Pharmaceuticals Appoints Zeil Rosenberg, M.D., M.P.H., as Executive Vice President, Medical for Infectious Disease ProgramsGlobeNewsWire • 01/04/23
Tonix Pharmaceuticals Achieves Enrollment of First 50 Percent of Participants in the RESILIENT Study, a Potentially Pivotal Confirmatory Phase 3 Study of TNX-102 SL for the Management of FibromyalgiaGlobeNewsWire • 12/19/22
Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized anti-SARS-CoV-2 Monoclonal Antibodies from Curia Global, Inc.GlobeNewsWire • 12/12/22
Tonix Pharmaceuticals Announces Collaboration with Boston Children's Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in AnimalsGlobeNewsWire • 12/05/22
Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral CongressGlobeNewsWire • 11/30/22
